These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20572362)

  • 21. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
    Wise J
    BMJ; 2012 Feb; 344():e1360. PubMed ID: 22362460
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
    Chiba K; Kataoka H
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumefactive multiple sclerosis lesions under fingolimod treatment.
    Visser F; Wattjes MP; Pouwels PJ; Linssen WH; van Oosten BW
    Neurology; 2012 Nov; 79(19):2000-3. PubMed ID: 23035065
    [No Abstract]   [Full Text] [Related]  

  • 25. Avoiding infusion therapy prime benefit of new MS drug.
    Morrow T
    Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
    [No Abstract]   [Full Text] [Related]  

  • 26. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA; Lapierre Y; Bar-Or A; Antel JP
    Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gilenya safety update: cardiac and macula.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2012 Nov; 23(6):457-9. PubMed ID: 23047163
    [No Abstract]   [Full Text] [Related]  

  • 28. Transforming multiple sclerosis trials into practical reality.
    Kieseier BC; Wiendl H
    Lancet Neurol; 2011 Jun; 10(6):493-4. PubMed ID: 21571592
    [No Abstract]   [Full Text] [Related]  

  • 29. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
    Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S
    Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 32. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
    Goldman MD; Naismith RT
    Neurology; 2015 Mar; 84(9):864-5. PubMed ID: 25636716
    [No Abstract]   [Full Text] [Related]  

  • 33. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Tully T; Barkley A; Silber E
    Neurology; 2015 May; 84(19):1999-2001. PubMed ID: 25878178
    [No Abstract]   [Full Text] [Related]  

  • 35. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
    Hopkins CR
    ACS Chem Neurosci; 2011 Mar; 2(3):116-7. PubMed ID: 22778861
    [No Abstract]   [Full Text] [Related]  

  • 36. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 37. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 38. [New therapies in multiple sclerosis].
    Roggerone S; Chenevier F; Confavreux C; Vukusic S
    Rev Prat; 2012 Oct; 62(8):1057-60. PubMed ID: 23227596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infections cast cloud over Novartis' MS therapy.
    Garber K
    Nat Biotechnol; 2008 Aug; 26(8):844-5. PubMed ID: 18688218
    [No Abstract]   [Full Text] [Related]  

  • 40. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
    Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C
    Ann Neurol; 2011 Feb; 69(2):408-13. PubMed ID: 21387383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.